Follicular Lymphoma
Conference Coverage
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
Article
Aggressive B-Cell Non-Hodgkin Lymphoma
News
Umbralisib has ‘distinct’ safety profile
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
Article
2017 notches up some landmark approvals
News
Drug granted fast track designations for FL, DLBCL
The US Food and Drug Administration (FDA) has granted 2 fast track designations to 5F9, an anti-CD47 antibody. The designations are for 5F9 as a...
Conference Coverage
Early results favor combo IL-15/anti-CD20 in indolent NHL
CHICAGO – The researchers tested the combination of rituximab with the IL-15 receptor super agonist complex ALT-803.
News
Novartis CAR T-cell therapy adds a lymphoma indication
The new approval puts tisagenlecleucel head to head with Gilead’s axicabtagene ciloleucel.
News
FDA issues CRL for proposed biosimilar rituximab
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed...
News
FDA approves CAR T-cell therapy for lymphoma
The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah®) for its second indication. The chimeric antigen receptor (CAR)...
News
Team identifies 5 subtypes of DLBCL
New research has revealed 5 genetic subtypes of diffuse large B-cell lymphoma (DLBCL). Researchers identified a group of low-risk activated B-cell...